Advisory · Gastroenterology
IBD and liver disease drive the majority of GI deal activity.
Ambrosia provides senior-led advisory for gastroenterology licensing, M&A, and strategic partnerships — backed by a proprietary database of 40 verified gastroenterology transactions.
Deal Landscape
What gastroenterology transactions actually look like.
Verified Transactions
40
Median Upfront
$55M
Key Structure Insight
IBD biologics and MASH/NASH represent distinct deal structure patterns
Related Insights
Research relevant to gastroenterology.
Discuss your gastroenterology transaction.
We’ll meet you at peer level — anywhere in the world.